Pediatric Epidermolysis Bullosa

Updated: Nov 12, 2021
  • Author: Surasak Puvabanditsin, MD; Chief Editor: Dirk M Elston, MD  more...
  • Print


Epidermolysis bullosa (EB) is a rare group of inherited disorders that manifests as blistering or erosion of the skin and, in some cases, the epithelial lining of other organs, in response to little or no apparent trauma. See the image below.

Ruptured bulla and newly erupted bulla of the leg Ruptured bulla and newly erupted bulla of the leg in a newborn with epidermolysis bullosa simplex (EBS).

See 13 Common-to-Rare Infant Skin Conditions, a Critical Images slideshow, to help identify rashes, birthmarks, and other skin conditions encountered in infants.

More than 30 types of epidermolysis bullosa have been described, rendering categorization of the types controversial and often confusing. An international consensus meeting in Vienna, Austria in 2008 reaffirmed the following currently used names for the four major types of epidermolysis bullosa [1] :

  • Epidermolytic - Epidermolysis bullosa simplex (EBS)

  • Lucidolytic - Junctional epidermolysis bullosa (JEB)

  • Dermolytic - Dystrophic epidermolysis bullosa (DEB)

  • Multiple levels of blistering - Kindler syndrome

These major types were based on the precise ultrastructural level at which the split responsible for blistering occurs. The leading authority on epidermolysis bullosa added Kindler syndrome as the fourth major epidermolysis bullosa type in 2008 with a unique clinical phenotype—photosensitivity. [1]

The three main types of epidermolysis bullosa were clinically and histologically delineated by the 1960s. [2] In the 1970s, electron microscopy revealed abnormal epidermal keratin filaments in epidermolysis bullosa simplex, disordered dermal anchoring fibrils in dystrophic epidermolysis bullosa, and defective hemidesmosomes in junctional epidermolysis bullosa. Antigens identified with immunohistochemistry in the 1980s [3, 4] led to discovery of the major epidermolysis bullosa genes in the 1990s. [5, 6, 7]

The identified genes include those that encode keratins 5 and 14 in epidermolysis bullosa simplex, collagen VII in dystrophic epidermolysis bullosa, and laminin 5 in Herlitz junctional epidermolysis bullosa. Toward the end of millennium, as the complex structure of desmosomes and hemidesmosomes was unraveled, the genes responsible for the rare subtypes were found, including those that encode α6β4 integrin in epidermolysis bullosa with pyloric atresia, plectin in epidermolysis bullosa with muscular dystrophy, and plakophilin in epidermolysis bullosa with ectodermal dysplasia.

During the past few years, systemic data collection and analysis have been performed on several thousands of patients with epidermolysis bullosa worldwide, and more than 1000 mutations, encompassing more than 10 structural genes, have now been documented. More has been learned about the molecular basis of epidermolysis bullosa, a group of diseases that shares clinical or molecular features with several other genodermatoses. 

Eponyms associated with different forms of epidermolysis bullosa include the following:

  • Dowling-Meara

  • Köebner

  • Weber-Cockayne

  • Kallin

  • Mendes de Costa

  • Herlitz

  • Ogna

  • Carmi

  • Cockayne-Touraine

  • Pasini

  • Hallopeau-Siemens

  • Shabbir

  • Laryngoonychocutaneous (LOC)



Cytolysis causes blisters in the epidermis or basement membrane zone of the skin. In epidermolysis bullosa simplex, cytolysis causes blisters in the basal or spinous layers of the epidermis, and keratinocytes often have abnormal density and organization of keratin filaments. In junctional epidermolysis bullosa, the epidermis separates from the basal lamina, forming a blister cavity in the plane of the lamina lucida, where hemidesmosome structure and density are frequently diminished. In dystrophic epidermolysis bullosa, the basal lamina remains attached to the epidermis, but the blister cavity forms beneath the lamina densa of dermoepidermal junction, and anchoring fibrils may appear abnormal, reduced in number, or altogether absent.




United States

The exact prevalence of epidermolysis bullosa is unknown. Mild variants have been estimated to occur as frequently as 1 per 50,000 births. The more severe varieties are believed to occur in 1 per 500,000 births annually.

Between 1986 and 2002, the National Institutes of Health (NIH) funded the National EB Registry (NEBR), a cross-sectional and longitudinal epidemiological study of epidermolysis bullosa patients across the entire continental United States. Nearly 3300 epidermolysis bullosa patients were identified, enrolled, classified, clinically characterized, and followed for outcomes. The incidence and prevalence of epidermolysis bullosa was estimated at approximately 19 cases per 1 million live births and 11 cases per 1 million population. [8, 9] These data were then used to estimate carrier frequencies for epidermolysis bullosa within the United States, which is between 1 in 300 and 1 in 800. [10]

The prevalence of inherited epidermolysis bullosa subtypes in the United States in January 2002, based on the NEBR was as follows [9] :

  • Epidermolysis bullosa simplex - 6 cases per 1 million population
  • Junctional epidermolysis bullosa - 0.49 case per 1 million population
  • Dominant dystrophic epidermolysis bullosa - 1.49 cases per 1 million population
  • Recessive dystrophic epidermolysis bullosa - 1.35 cases per 1 million population

The incidence of inherited epidermolysis bullosa subtypes in the United States from 1986 to 2002, based on the NEBR was as follows [9] :

  • Epidermolysis bullosa simplex - 7.87 cases per 1 million live births
  • Junctional epidermolysis bullosa - 2.68 per 1 million live births
  • Dominant dystrophic epidermolysis bullosa - 12.12 per 1 million live births
  • Recessive dystrophic epidermolysis bullosa - 3.05 per 1 million live births


The point prevalence of all forms of epidermolysis bullosa in Scotland was 49.0 cases per million, comprising epidermolysis bullosa simplex at 28.6 cases per million and dystrophic epidermolysis bullosa at 20.4 cases per million population. [11]

The incidence rate of new cases of epidermolysis bullosa diagnosed per year in Northern Ireland during a 23-year period (1962-84) is 1.4 cases per million and the prevalence of all forms estimated at 32 cases per million population. The prevalence of simplex, junctional, and dystrophic forms is 28 cases, 0.7 case, and 3 cases per million population, respectively. [12]

The estimated prevalence of each type of epidermolysis bullosa in Japan was as follows: simplex type, 2.9-4 cases per million population; junctional type, 0.15-0.20 cases per million population; dominant dystrophic type, 1.1-1.5 cases per million population; and recessive dystrophic type, 1.5-2.1 cases per million population. [13]

The prevalence of epidermolysis bullosa in Croatia, Yugoslavia, from 1960-1987 was 9.5 cases per million population. [14]

In the United Kingdom, prevalence rates of epidermolysis bullosa have been estimated to range from 15-32 cases per million population. [11, 12, 15]

Data from the Australasian EB Registry provided a prevalence estimate of 10 cases per million live births. [16]


The epidermolysis bullosa simplex Ogna variant has been described in Norwegian individuals.


Epidermolysis bullosa is an autosomal inherited disorder. The incidence does not differ by sex.


The onset of epidermolysis bullosa simplex is at birth or early infancy. The onset of junctional epidermolysis bullosa is at birth. The onset of dystrophic epidermolysis bullosa is at birth or early childhood. The onset of Kindler syndrome is usually within the first year of life.



Epidermolysis bullosa is chronic. Patients should restrict and modify their activity to avoid the serious complications of blistering. Depending on the type of epidermolysis bullosa, disease severity may range from occasional mild blistering of the hands and feet to severe and widespread formation of bullae. These lesions may result in nonhealing erosions, infection, scarring, and joint contracture. Mortality is also related to the abnormalities or anomalies associated with epidermolysis bullosa.

Epidermolysis bullosa continues to be devastating disease with high incidence of aggressive squamous cell carcinoma (SCC). SCC is the most serious complication of epidermolysis bullosa within adults, especially those with Hallopeau-Siemens recessive dystrophic epidermolysis bullosa. By mid adulthood, nearly all patients have had at least one SCC, and nearly 80% die from metastatic SCC. [17] recessive dystrophic epidermolysis bullosa SCC is highly aggressive and has early metastatic spread. Recessive dystrophic epidermolysis bullosa SCC most commonly occurs in chronic nonhealing ulcers and over bony prominences on limbs where UV light exposure is minimal. Unlike most cancers, recessive dystrophic epidermolysis bullosa SCC is generally well-differentiated but behaves in a highly aggressive manner and has high metastatic potential. [18]

Risk of death from renal disease is noted. Causes include renal failure, poststreptococcal glomerulonephritis, secondary amyloidosis, and chronic mechanical obstruction. The cumulative risk of death from renal failure among patients with Hallopeau-Siemens recessive dystrophic epidermolysis bullosa is 12.3% by age 35 years. [19]  Death may occur during infancy or early childhood, due to sepsis, renal failure, upper airway occlusion, or failure to thrive. [19, 20]

Healing of dystrophic epidermolysis bullosa results in dystrophic or scarring change. In epidermolysis bullosa simplex, when blisters cleave in the epidermis, healing occurs without scarring. In junctional epidermolysis bullosa, when blisters cleave below the epidermis but above the basal lamina, blistering leads to mild atrophic changes.